IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (306)	1/27/1997 1:08:00 PM
From: Richard Belanger	of 1762

ImmunoGen (IMGN) announced last week they received a patent for a technology to produce "humanized" mouse antibodies. They also have an immunoconjugate in Phase III trials for lymphoma and 3 small molecule products in preclinical development. I would be most interested in your opinion regarding the potential threat of this technology to Idec's primatized antibodies. Apparently, the mouse-based products would have much greater appeal in terms of large-scale production. Also, do you have any opinion on IMGN as a stock? Thanks, Rich

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next